ZD-6474 AstraZeneca

Current Opinion in Investigational Drugs

Volumn 4, Issue 12, 2003, Pages 1468-1472

  Bates, David ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; GEFITINIB; GEMCITABINE; N (4 BROMO 2 FLUOROPHENYL) 6 METHOXY 7 [2 (1H 1,2,3 TRIAZOL 1 YL)ETHOXY] 4 QUINAZOLINAMINE; N ACETYLCOLCHINOL PHOSPHATE; PROTEIN TYROSINE KINASE; STEROID; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN RECEPTOR KINASE;

CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG ERUPTION; DRUG HALF LIFE; DRUG INDICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG SYNTHESIS; ENZYME INHIBITION; FATIGUE; HUMAN; HYPERTENSION; LD 50; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MYELOMA; NAUSEA; NONHUMAN; PROTEINURIA; QT PROLONGATION; REVIEW; SKIN DISEASE; SOLID TUMOR; STRUCTURE ACTIVITY RELATION; THROMBOCYTOPENIA; TOXICITY TESTING; WEIGHT REDUCTION;

ANIMALS; CLINICAL TRIALS; DRUGS, INVESTIGATIONAL; ENZYME INHIBITORS; HUMANS; NEOPLASMS; PIPERIDINES; QUINAZOLINES; TECHNOLOGY, PHARMACEUTICAL;

EID: 1642515721     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. 321926 SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A Cancer Res 1999 59 1 99-106
2. 330958 Vascular endothelial growth factor (VEGF) and its receptors. Neufeld G, Cohen T, Gengrinovitch S, Poltorak Z Faseb J 1999 13 1 9-22
3. 349551 AstraZeneca progresses key products and aims to double product portfolio value every five years. AstraZeneca plc Press Release 1999 December 06
4. 362509 VEGF receptor tyrosine kinase inhibitors as potential anti-tumor agents. Wedge SR, Oglivie DJ, Dukes M, Kendrew J, Hennegiun LF, Stokes ESE, Curry B Proc Annu Meet Am Assoc Cancer Res 2001 41 Abs 3610
5. 370391 PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Wood JM, Bold G, Buchdunger E, Cozens R, Ferrari S, Frei J, Hofmann F, Mestan J, Mett H, O'Reilly T, Persohn E et al. Cancer Res 2000 60 8 2178-2189
6. 404626 American Association for Cancer Research 92nd Annual Meeting (Part IX), New Orleans, LA, USA. Boven E IDDB Meeting Report 2001 March 24-28
7. 410016 Phase I pharmacokinetic and biological study of the angiogenesis inhibitor ZD6474, in patients with solid tumors. Basser R, Hurwitz H, Barge A, Davis I, DeBoer DR, Holden S, McArthur G, McKinley M, Nairn K, Persky M, Rischin D et al. Proc Am Soc Clin Oncol 2001 20 1 Abs 396
8. 411418 American Society of Clinical Oncology - 37th Annual Meeting (Part X), San Francisco, CA, USA. Morse M IDDB Meeting Report 2001 May 12-15
9. 422526 RSC-SCI Medicinal Chemistry - 11th Symposium (Part I), Cambridge, UK. Norman P IDDB Meeting Report 2001 September 9-12
10. 429792 A phase I study of ZD6474, an oral VEGF receptor tyrosine kinase inhibitor, in patients with solid tumors. Hurwitz HI, Eckhardt SG, Holden SN, Basser R, Deboer R, Rosenthal M, Rischin D, Swaisland H, Barge A, McKinley M, Wheeler C AACR NCI EORTC Mol Targets Cancer Ther 2001 October 29-November 2 Abs 5
11. 431305 Effects of ZD6474, an orally active inhibitor of VEGF receptor tyrosine kinase, in patients with solid tumors: Results from a phase I study. Holden S, Eckhardt S, Basser R, Rischin D, Hurwitz H, DeBoer R, Rosenthal M, Saisland H, McKinley M, Schachter L Eur J Cancer 2001 37 Suppl 6 S73 Abs 257
12. 444173 Novel 4-anilinoquinazolines with C-7 basic side chains: Design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. Hennequin LF, Stokes ESE, Thomas AP, Johnstone C, Ple PA, Ogilvie DJ, Dukes M, Wedge SR, Kendrew J, Curwen JO J Med Chem 2002 45 6 1300-1312
13. 447345 Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase. Ciardiello F, Caputo R, Damiano V, Vitagliano D, Carlomagno F, Santoro M, Fontanini G, Bianco AR, Tortora G Proc Annuo Meet Am Assoc Cancer Res 2002 43 Abs 5348
14. 447356 Combination of the VEGF receptor tyrosine kinase inhibitor ZD6474 and vascular-targeting agent ZD6126 produces an enhanced anti-tumor response. Wedge SR, Kendrew J, Ogilvie DJ, Hennequin LF, Brave SR, Ryan AJ, Ashton SE, Calvete JA, Blakey DC Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 5351
15. 447398 Effect of ZD6474, a VEGF receptor tyrosine kinase inhibitor, on primary tumor growth, metastasis, vessel density and microvascular architecture in murine renal cell carcinoma. Drevs J, Esser N, Konerding MA, Wolloscheck T, Wedge SR, Ryan AJ, Ogilvie DJ, Unger C, Marme D Proc Annu Meet Am Assoc Cancer Res 2002 43 Abs 5358
16. 452196 Clinical evaluation of ZD6474, an orally active inhibitor of VEGF signaling, in patients with solid tumors. Hurwitz H, Holden SN, Eckhardt SG, Rosenthal M, De Boer R, Rischin D, Green M, Basser R Proc Am Soc Clin Oncol 2002 21 1 Abs 325
17. 469322 AstraZeneca development pipeline: NCEs and line extensions - 7 November 2002. AstraZeneca Plc Company World Wide Web Site 2002 November 07
18. 469329 Annual Business Review press release: AstraZeneca reports significant progress across its promising research and development portfolio. AstraZeneca Plc Press Release 2002 November 07
19. 469330 AstraZeneca's Annual Business Review 2002. Analyst presentation. AstraZeneca Plc Company Presentation 2002 November 07
20. 470792 Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR [KDR]-TKI), in a model of ZD1839 ('Iressa') resistance. Taguchi F, Koh Y, Koizumi F, Ueda Y, Tsukiyama S, Tamura T, Saijo N, Nishio AACR NCI EORTC Mol Targets Cancer Ther 2002 14 Abs 192
21. 478130 ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Wedge SR, Ogilvie DJ, Dukes M, Kendrew J, Chester R, Jackson JA, Jackson SJ, Valentine PJ, Curwen JO, Musgrove HL, Graham GA et al. Cancer Res 2002 62 16 4645-4655
22. 479313 Angiogenesis - SMi Conference, London, UK. Mazucco RA IDDB Meeting Report 2003 February 18-19
23. 484072 Implications of anti-angiogenic treatment with ZD6474, a potent and selective VEGFR tyrosine kinase inhibitor, for tumor behavior in a mice model of brain metastasis. Leenders W, Kuesters B, Verrijp K, Maass C, Heerschap A, Ruiter D, De Waal R Proc Annu Meet Am Assoc Cancer Res 2003 44 Abs 37
24. 484079 ZD6474, a potent inhibitor of VEGF signaling, combined with radiotherapy: Schedule-dependent enhancement of anti-tumor activity in a lung tumor xenograft model. Williams KJ, Telfer BA, Stratford IJ, Wedge SR Proc Annu Meet Am Assoc Cancer Res 2003 44 Abs 41
25. 484081 ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase activity, inhibits growth of human non-small cell lung cancer metastases that are resistant to treatment with ZD1839. Matsumori Y, Goto H, Nakataki E, Kanematsu T, Yano S, Wedge S, Ryan A, Sone S Proc Annu Meet Am Assoc Cancer Res 2003 Abs 43
26. 484085 ZD6474, a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor, inhibits central nervous system tumor growth following oral administration. Rich JN, Keir ST, Wheeler C, Reardon DA, Bigner DD, Friedman HS Proc Annu Meet Am Assoc Cancer Res 2003 44 Abs 48
27. 484818 Regulation of microvascular permeability by vascular endothelial growth factors. Bates DO, Hillman NJ, Williams B, Neal CR, Pocock TM Abs 48 2000 200 6 581-597
28. 484819 Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer. Brown LF, Berse B, Jackman RW, Tognazzi K, Guidi AJ, Dvorak HF, Senger DR, Connolly JL, Schnitt SJ Hum Pathol 1995 26 1 86-91
29. 484820 Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Dvorak HF, Brown LF, Detmar M, Dvorak AM Am J Pathol 1995 146 5 1029-1039
30. 484822 Isolation of a tumor factor responsible or angiogenesis. Folkman J, Merler E, Abernathy C, Williams G J Exp Med 1971 133 2 275-288
31. 484826 Design and structure-activity relationship of a new class of potent VEGF receptor tyrosine kinase inhibitors. Lohmann JJ, Ogilvie DJ, Dukes M, Wedge SR, Curwen JO, Kendrew J, Van Der Lambert BC J Med Chem 1999 42 26 5369-5389
32. 484827 Role of vascular endothelial growth factor in angiogenesis of rheumatoid arthritis. Nagashima M, Yoshino S, Ishiwata T, Asano G J Rheumatol 1995 22 9 1624-1630
33. 484833 Vascular endothelial growth factor and its receptor. Neufeld GS, Tessler H, Gitay-Goren T, Cohen BZ Prog Growth Factor Res 1994 5 89-97
34. 484844 ZM323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. Whittles CE, Pocock TM, Wedge SR, Kendrew J, Hennequin LF, Harper SJ, Bates DO Microcirculation 2002 9 6 513-522
35. 492029 A phase I study of an oral VEGF receptor tyrosine kinase inhibitor ZD6474, in Japanese patients with solid tumors. Minami H, Ebi H, Tahara M, Sasaki Y, Yamamoto N, Yamada Y, Tamura T, Saijo N Proc Am Soc Clin Oncol 2003 22 Abs 778
36. 496170 International Meeting on Angiogenesis in Cancer, Reykjavik, Iceland. Leenders W IDDB Meeting Report 2003 June 26-28
37. 496891 Latest research data strengthens the evidence for AstraZeneca's new anti-vascular approaches to beat cancer. AstraZeneca Plc Press Release 2003 July 11
38. 497154 AstraZeneca reports on anti-vascular approaches to treat cancer. AstraZeneca Plc Press Release 2003 July 14
39. 497455 Anti-angiogenic and anti-tumor activity of a novel VEGFR-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. Bruns CJ, Kohl G, Guba M, Yezhelyev M, Wiegand U, Ryan A, Barge A, Geissler EK, Jauch KW Proc Annu Meet Am Assoc Cancer Res 2003 44 Abs 3041
40. 498925 Activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR (KDR)-TKI), in a model of ZD1839 (Iressa) resistance. Taguchi F, Koizumi F, Shimoyama T, Saijo N, Nishio K Proc Annu Meet Am Assoc Cancer Res 2003 44 4880
41. 507569 Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Ciardiello F, Caputo R, Damiano V, Caputo R, Troiani T, Vitagliano D, Carlomagno F, Veneziani BM, Fontanini G, Bianco AR, Tortora G Clin Cancer Res 2003 9 4 1546-1556